Sources Listing Archive
Archived Listing - Last Updated: September 2006. This information represents a historical archive of listings which appeared in SOURCES, which has been continuously published in print and online since 1977. The information has not been updated since the date indicated. For current information consult the SOURCES website at www.sources.com. To be included in the current SOURCES listings, and to take advantage of other tools including unlimited news releases and event calendar postings, fill out the online membership form. For more information, see Frequently Asked Questions or call 416-964-7799.

Find Experts & Sources
Media coverage for your story
Neurochem Inc.
Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders.The company's pipeline of proprietary, disease-modifying oral products addresses critical unmet medical needs. Fibrillex, designated an orphan drug, has completed a Phase II/III clinical trial for AA Amyloidosis, and the Company is in the process of submitting an NDA that the FDA has agreed to file and review. Alzhemed is currently in a North American as well as European Phase III clinical trials for the treatment of Alzheimer's disease. Cerebril has completed a Phase II clinical trial for the prevention of hemorrhagic stroke caused by cerebral amyloid angiopathy.

Areas of Expertise:


For information or updates contact Sources at 416-964-7799 or see our current publications and services online:

The Sources Directory     Include yourself in Sources     Media Names & Numbers

Sources Calendar     News Releases     Parliamentary Names & Numbers

© Sources 1977-2012. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.